@MyelomaTeacher - Cindy Chmielewski
@MyelomaTeacher
Retired Teacher- Dx with Myeloma 2008- Patient Research Advocate-Curriculum Director @HealthTreeU- @ASH_Hematology & @TheEBMT Speaker-IRB Member, #MMSM
Happy to see patients as influencers at major medical meetings. It is so important to include all perspectives in the conversations. #MMsm #ASH24 #HealthTree #myeloma
How is the P-Crowd Helping Advance Myeloma Research? youtu.be/WoUZzbtZ0DI?fe… #mmsm @HealthTree
The “missed opportunity” will be for myeloma patients if thus is not FDA approved.
‘Missed Opportunity’: GSK Failed To Optimize Blenrep Dosage, US FDA Panel Says — Click image below to read more! || #PinkSheet | Start your free trial today: vist.ly/3yaz6 vist.ly/3yaz7
I couldn’t agree more! Patients should be weighing the risks vs benefits. They are the only ones who can decide if the product’s benefits outweigh the potential risks. The FDA should value are opinion.
I cannot begin to imagine dealing with myeloma and / or these type of side effects. However I am in favor of the freedom of patients and care givers to decide the risk / benefit profile. I have had patients lives given back to them from a dose of blenrep q3 months in CR
I hope it’s approved too! #mmsm
2 negative odac votes for blenrep. I missed the discussion but this drug has a role in myeloma. Hoping the fda still approves it. #mmsm
1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.
Congratulations, @RahulBanerjeeMD on the publication on this global myeloma study! Thank you for including me. This study will always hold a special place in my heart .. it’s my 1st publication as co-author after I joined @CCHRCCancerCare .. plenty of work to do together! #mmsm🌿
1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.
Yesterday Blenrep was approved in Canada - today Blenrep was approved in the EU. This myeloma patient and research advocate hopes that by October the @US_FDA GIVES Blenrep the green light too. #mmsm gsk.com/en-gb/media/pr…
A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. @thanosdimop @PlasmaCellPete globenewswire.com/news-release/2…
Blenrep Combinations are approved in Canada. This myeloma patient and research advocate is still hopeful the @US_FDA will follow suit! #mmsm ca.gsk.com/en-ca/media/pr…
A big first for SMM! EU clears J&J's Darzalex as first therapy for smoldering multiple myeloma. Congrats to the entire #myeloma community who fought hard for this to happen #mmsm. firstwordpharma.com/story/5983164
FDA extends review period for GSK’s Blenrep in multiple myeloma #mmsm za.investing.com/news/company-n…
I hope the @FDA realizes the benefit this drug provides when they make their final decision.
FDA Advisory Committee Rejects Blenrep Combo Therapies—But a Positive Vote is Possible for Myeloma Patients Seeking New Options healthtree.org//myeloma/commu….
I was dx in 2008- This is a blessing. #mmsm
Dramatic progress in myeloma over last 20 years. Small font but download and use. 19 new drug approvals in 20 years.
The DREAMM studies have proven Belantamab effective and that the eye-related side effects can be mitigated. Eye related side effects are nothing to take lightly, but patients should have the right to decide for themselves what risks they are willing to take. #mmsm
I likewise don’t discount how onerous these side effects can be, but Bela is less dangerous than other approved therapies with serious life-threatening toxicity like CAR T and bispecifics, which we are trusted to manage and offer to pts with informed consent.
Check out HealthTree University’s newest lesson -All About Kyprolis (Carfilzomib) - Updated 2025 -this video also discusses the Real World dosing options. #myeloma youtu.be/3uLX-A7F4xQ?fe… #mmsm @HealthTree
I’m still in disbelief.The job of the @FDA according to their website is to “protect the public health by assuring the safety, efficacy, and security of human and veterinary drugs”. DREAMM Trials have proven Blenrep’s efficacy & have shown that the drug can be safely given. #mmsm
Indeed a shocker! If a drug going against an anti CD38 antibody head to head in a phase III trial shows a survival benefit, a vote against it makes no sense! Toxicity is manageable with appropriate dose reductions and dose intensity! Bela has made a real difference to patients!
BTW - In NJ I don’t qualify for an “unrestrictive drivers license”. My driver’s license states I must wear glasses. Just saying. #mmsm
Why do many regulatory oncology phase III trials not accrue sufficient US patients? This issue came up repeatedly at today’s ODAC for belantamab for myeloma. And I can address it at least for myeloma. 1) In our healthcare system, opening a trial in a timely manner is a…
I hope so! - The questions were worded to achieve a no vote. The drug is effective- the drug is safe. Bottom line. #mmsm.
Shocker for me. ODAC votes against belantamab risk benefit for myeloma. I hope that this vote reflects the way the questions were narrowly worded. I still hope the drug still gets FDA approved.
You say things much more eloquently than me-but I agree 1000% #mmsm @FDA #ODAC
I agree... I prefer to have One more option. One more change. One more Hope! And working with my myeloma specialists and attending clinicians to manage the toxicity.